166571
Public health risk assessment and epidemiology of acute contamination with 210Polonium, London, October-November 2006
Wednesday, November 7, 2007: 8:55 AM
Graham Fraser, FFPH
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Helen Maguire, FFPH
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Mike Bailey, Dr
,
Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Radiation Protection Division, Ditcot Oxon, UT, United Kingdom
George Etherington, Dr
,
Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Radiation Protection Division, Ditcot Oxon, UT, United Kingdom
Louise Bishop, MPH
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Mike Youngman, Dr
,
Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Radiation Protection Division, Ditcot Oxon, UT, United Kingdom
Alan Johnson
,
Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards, Radiation Protection Division, Ditcot Oxon, UT, United Kingdom
Sandra Cohuet, Dr
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Sarah Forrester, BS
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Lucy Thomas, Dr
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Ruth Ruggles, FPH
,
South West London Health Protection Unit, Health Protection Agency, London, United Kingdom
Deborah Turbitt, FPH
,
North East & North Central London Health Protection Unit, Health Protection Agency, London, United Kingdom
Roger Gross, FRCPath
,
Epidemiology Unit London Region, Health Protection Agency, London, United Kingdom
Introduction Several hundred persons across multiple locations were assessed for the possibility of acute exposure during the London 210Polonium incident of October-November 2006. This paper describes the public health risk assessment process and the epidemiology of acute exposure to 210Po for persons at risk during this incident. Methods: Locations identified as potentially contaminated with 210Po were assessed for the environmental contamination by monitoring teams of the Health Protection Agency's Radiation Protection Division. Persons associated with sites sufficiently contaminated to warrant risk assessment were interviewed by Agency public health consultants. Urine testing for 210Po was offered to individuals whose assessment indicated potential risk of contamination. Acute exposure to 210Po contamination was defined conservatively as urinary excretion of more than 30mBq/24h. Assessment of committed radiation dose was also carried out. Results: Nine hundred and ninety persons were risk assessed across ten locations, including three hotels, three offices, two hospitals and two restaurants. Family and contacts of the index case were also assessed. Seven hundred and seventy nine persons were offered 210Po urine testing, of which 137 had evidence of acute exposure. Committed dose assessments indicated low level potential health concern for 17 persons; no symptomatic cases were detected. Acute contamination was associated with particular locations, occupations, behavioural and other factors: this epidemiology will be described. Conclusions: A substantial number of persons across several sites and occupations had evidence of acute exposure in the London 210Po incident. Accumulating information on exposure epidemiology facilitated risk minimization, identification and reassurance of people at risk.
Learning Objectives: Appreciation of the epidemiology, and environmental and public health risk assessment processes for a dispersed radiaoctive community contamination incident
Keywords: Epidemiology, Radiation
Presenting author's disclosure statement:Any relevant financial relationships? No Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|